Tag: Atai Life Sciences - Page 6 - Psychedelic Alpha

Read more about the article DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

Post published:September 21, 2021
Post category:Press Release

Read more about the article atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

Post published:September 15, 2021
Post category:Press Release

Read more about the article Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

Post published:September 14, 2021
Post category:Press Release

Read more about the article atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

Post published:September 9, 2021
Post category:Press Release

Read more about the article atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

Post published:August 16, 2021
Post category:Press Release

Read more about the article atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

Post published:August 12, 2021
Post category:Press Release

Read more about the article atai Life Sciences launches InnarisBio to advance delivery of therapeutics for mental health disorders with a licence to develop novel sol-gel intranasal drug delivery platform technology from UniQuest

atai Life Sciences launches InnarisBio to advance delivery of therapeutics for mental health disorders with a licence to develop novel sol-gel intranasal drug delivery platform technology from UniQuest

Post published:July 28, 2021
Post category:Press Release

Read more about the article atai Life Sciences Announces Pricing of Upsized Initial Public Offering

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Post published:June 17, 2021
Post category:Press Release

Read more about the article atai Life Sciences Announces Launch of Initial Public Offering

atai Life Sciences Announces Launch of Initial Public Offering

Post published:June 11, 2021
Post category:Press Release

Read more about the article Atai Targets $2.3bn Valuation in Nasdaq IPO

Atai Targets $2.3bn Valuation in Nasdaq IPO

Post published:June 11, 2021
Post category:News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.